Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Monk, Bradley J.; Tewari, Krishnansu S.; Dubot, Coraline; Caceres, M Valeria; Salman, Pamela; Yañez, Eduardo; Gümüş, Mahmut; Mendoza, Mivael Olivera Hurtado de; Samouëlian, Vanessa; Castonguay, Vincent; Alexander, Arkhipov; Tekin, Cumhur; Li, Kan; Nguyen, Allison Martin; Monberg, Matthew J.; Colombo, Nicoletta; Lorusso, Domenica

doi:10.1016/s1470-2045(23)00052-9

Cited by 34 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A statistically significant OS benefit was seen in those who used carboplatin [ 3 ]. Lastly, health-related quality of life in patients who received pembrolizumab found that the addition of pembrolizumab to chemotherapy with or without bevacizumab did not negatively affect health-related quality of life [ 30 ]. This supports the value of pembrolizumab in those with rmCC.…”

Section: First Line Therapy For Recurrent/metastatic Cervical Cancermentioning

confidence: 99%

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

García,

Ayoub,

Tewari

2024

J Gynecol Oncol

View full text Add to dashboard Cite

Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.

show abstract

Section: First Line Therapy For Recurrent/metastatic Cervical Cancermentioning

confidence: 99%

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

García,

Ayoub,

Tewari

2024

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…The data showed that compared to the placebo group, the median time to true deterioration (TTD) was longer in the pembrolizumab group. In addition, patients in the pembrolizumab group experience fewer cervical symptoms of lymphoedema, menopausal symptoms, and peripheral neuropathy than the placebo group ( 80 ). Therefore, anti-PD-1 treatment could improve OS and PFS and was not accompanied by a decrease in health-related quality of life in patients with recurrent, persistent, or metastatic cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge

Li¹,

Cang²,

Gu³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Cervical cancer is one of the three major female gynecological malignancies, becoming a major global health challenge. Although about 90% of early-stage patients can be cured by surgery, advanced-stage patients still need new treatment methods to improve their efficacy, especially for those with recurrence and metastasis tumors. Anti-PD-1 is currently the most widely used immune checkpoint inhibitor, which has revolutionized cancer therapy for different types of cancer. Pembrolizumab has been approved for second-line treatment of R/M CC but has a modest overall response rate of about 15%. Therefore, multiple types of anti-PD-1 have entered clinical trials successively and evaluated the efficacy in combination with chemotherapy, targeted therapy, and immunotherapy. At the same time, the dual specific antibody of PD-1/CTLA-4 was also used in clinical trials of cervical cancer, and the results showed better than anti-PD-1 monotherapy. In addition, anti-PD-1 has also been shown to sensitize radiotherapy. Therefore, understanding the current research progress of anti-PD-1 will better guide clinical application. This review summarizes ongoing clinical trials and published studies of anti-PD-1 monotherapy and combination therapy in the treatment of cervical cancer, as well as discusses the potential molecular biological mechanisms of combination, aiming to provide the basic evidence for support anti-PD-1 in the treatment of cervical cancer and new insights in combination immunotherapy.

show abstract

“…GHS quality of life improved in 122 of 290 patients treated in the pembrolizumab group compared to 85 of 297 patients treated in the placebo group. The study results indicate an improvement in the quality of life after adding pembrolizumab to treatment, which indicates the benefits of treatment with immunotherapy [ 77 ]. All studies describing clinical trials with bevacizumab in the cervical cancer are presented in Table 2 .…”

Section: Bevacizumab In the Treatment Of Gynecological Cancersmentioning

confidence: 99%

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives

Żak,

Satora,

Skrabalak

et al. 2024

Cancers

View full text Add to dashboard Cite

There were high hopes for the new antiangiogenic medicament, bevacizumab, which could inhibit the creation of new blood vessels through binding to isoform A of vascular endothelial growth factor (VEGF). However, it is not only blood vessels that are responsible for tumor cell spread. During the process of tumor growth, lymphangiogenesis is mediated by other members of the VEGF family, specifically VEGF-C and VEGF-D, which act independent to bevacizumab. Therefore, based on the mechanism of bevacizumab action and the processes of angio- and lymphangiogenesis, we formed three hypotheses: (1) if the lymph nodes in primary ovarian cancers are metastatic, the outcome of bevacizumab treatment is worsened; (2) concerning the second-line treatment, bevacizumab will act in a weakened manner if recurrence occurs in lymph nodes as opposed to a local recurrence; (3) patients treated by bevacizumab are more likely to have recurrences in lymph nodes. These hypotheses raise the issue of the existing knowledge gap, which concerns the effect of bevacizumab on metastatic lymph nodes.

show abstract

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 34 publications

References 19 publications

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives

Contact Info

Product

Resources

About